Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells. 2003

Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
Department of Gastroenterology, Renmin Hosptial of Wuhan University, China.

Acetylsalicylic acid (ASA) has been confirmed to inhibit proliferation and to induce apoptosis in human colorectal cancer cells in vitro. However, the mechanism by which ASA exhibits antiproliferative and proapoptotic effects in cyclooxygenase 2 (COX-2)-negative cells remains to be further elucidated. In the present study, SW480, a COX-2-negative colon cancer cell line, was treated with various concentrations of ASA (0, 2.5, 5, and 10 mM). The antiproliferative and proapoptotic effects of ASA were confirmed by MTT assay, flow cytometry of propidium iodide (PI)-stained cells, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay. After treatment with ASA, intracellular cyclic AMP (cAMP) levels were increased and the production of prostaglandin E2 (PGE2) was decreased. RT-PCR analysis revealed that treatment of ASA induced a concentration-dependent downregulation of cytosolic phospholipase A2 (cPLA2) mRNA expression in SW480 cells and also in two other colorectal cancer cell lines, Colo320 and HT-29 cells. Intracellular calcium levels were unaffected by ASA treatment. Our results indicate that the ASA-induced downregulation of cytosolic phospholipase A2 mRNA expression might be a novel mechanism for ASA-mediated growth inhibition and apoptosis in colon cancer cells.

UI MeSH Term Description Entries
D010741 Phospholipases A Phospholipases that hydrolyze one of the acyl groups of phosphoglycerides or glycerophosphatidates.
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
November 1998, Journal of immunology (Baltimore, Md. : 1950),
Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
January 2003, Clinical cancer research : an official journal of the American Association for Cancer Research,
Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
November 1993, The Biochemical journal,
Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
February 2007, Molecular carcinogenesis,
Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
September 2000, Journal of immunology (Baltimore, Md. : 1950),
Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
October 2000, Journal of immunology (Baltimore, Md. : 1950),
Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
April 1999, Cell,
Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
August 2004, Biological & pharmaceutical bulletin,
Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
March 1993, Agents and actions,
Hong-Gang Yu, and Jie-An Huang, and Yan-Ning Yang, and He-Sheng Luo, and Jie-Ping Yu, and Juris J Meier, and Henning Schrader, and Andreas Bastian, and Wolfgang E Schmidt, and Frank Schmitz
January 2023, Biomolecules & therapeutics,
Copied contents to your clipboard!